MX2021004173A - Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. - Google Patents
Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.Info
- Publication number
- MX2021004173A MX2021004173A MX2021004173A MX2021004173A MX2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- staphylococcus aureus
- protein
- aureus antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743490P | 2018-10-09 | 2018-10-09 | |
| US201962833297P | 2019-04-12 | 2019-04-12 | |
| PCT/US2019/055143 WO2020076789A2 (en) | 2018-10-09 | 2019-10-08 | Combinations of anti-staphylococcus aureus antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004173A true MX2021004173A (es) | 2021-09-08 |
Family
ID=70051346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004173A MX2021004173A (es) | 2018-10-09 | 2019-10-08 | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11168133B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3864041A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022512647A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210072057A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113164602A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019357983A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021006622A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3115633A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004173A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202035443A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020076789A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2917360B1 (en) * | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| WO2020076790A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
| MX2021004173A (es) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
| JP7682795B2 (ja) | 2019-03-13 | 2025-05-26 | メディミューン,エルエルシー | コロニー形成患者における黄色ブドウ球菌(Staphylococcus aureus)感染症の低減 |
| KR20230049584A (ko) * | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
| CN117771379B (zh) * | 2023-10-25 | 2024-08-30 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合 |
| CN121537524B (zh) * | 2026-01-20 | 2026-04-28 | 江西省人民医院 | 一种mda5人源化单克隆抗体及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| WO2002072600A2 (en) | 2001-01-26 | 2002-09-19 | Inhibitex, Inc. | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| ATE458006T1 (de) | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| JP2009539979A (ja) | 2006-06-12 | 2009-11-19 | ナビ バイオファーマシューティカルズ | ブドウ球菌感染症を治療および予防するための、α毒素の使用 |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトc−fms抗原結合性タンパク質 |
| KR20100072228A (ko) | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| KR20110044991A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | TNF-α 길항제 다-표적 결합 단백질 |
| EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| CN102387814A (zh) | 2009-01-29 | 2012-03-21 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| LT3444268T (lt) | 2010-05-05 | 2022-04-11 | New York University | Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai |
| RS58190B2 (sr) | 2011-02-08 | 2021-08-31 | Medimmune Llc | Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene |
| EP2917360B1 (en) | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| ES2912267T3 (es) | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| CN105873946A (zh) | 2013-10-17 | 2016-08-17 | 阿尔萨尼斯生物科学有限责任公司 | 交叉反应性金黄色葡萄球菌抗体序列 |
| JP6832709B2 (ja) | 2014-05-16 | 2021-02-24 | メディミューン,エルエルシー | 新生児Fc受容体結合が改変されて治療および診断特性が強化された分子 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| AU2016249837A1 (en) | 2015-04-17 | 2017-09-28 | Arsanis Biosciences Gmbh | Anti-staphylococcus aureus antibody combination preparation |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| MX2021004173A (es) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
| WO2020076790A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
-
2019
- 2019-10-08 MX MX2021004173A patent/MX2021004173A/es unknown
- 2019-10-08 JP JP2021519612A patent/JP2022512647A/ja not_active Ceased
- 2019-10-08 TW TW108136341A patent/TW202035443A/zh unknown
- 2019-10-08 US US16/596,388 patent/US11168133B2/en active Active
- 2019-10-08 AU AU2019357983A patent/AU2019357983A1/en not_active Abandoned
- 2019-10-08 CA CA3115633A patent/CA3115633A1/en active Pending
- 2019-10-08 KR KR1020217013653A patent/KR20210072057A/ko not_active Ceased
- 2019-10-08 EP EP19871705.0A patent/EP3864041A2/en not_active Withdrawn
- 2019-10-08 BR BR112021006622-5A patent/BR112021006622A2/pt not_active IP Right Cessation
- 2019-10-08 CN CN201980078574.1A patent/CN113164602A/zh active Pending
- 2019-10-08 WO PCT/US2019/055143 patent/WO2020076789A2/en not_active Ceased
-
2021
- 2021-10-01 US US17/491,889 patent/US20220089699A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3864041A2 (en) | 2021-08-18 |
| US20200109189A1 (en) | 2020-04-09 |
| CN113164602A (zh) | 2021-07-23 |
| WO2020076789A2 (en) | 2020-04-16 |
| US11168133B2 (en) | 2021-11-09 |
| KR20210072057A (ko) | 2021-06-16 |
| JP2022512647A (ja) | 2022-02-07 |
| AU2019357983A1 (en) | 2021-05-27 |
| CA3115633A1 (en) | 2020-04-16 |
| US20220089699A1 (en) | 2022-03-24 |
| TW202035443A (zh) | 2020-10-01 |
| WO2020076789A3 (en) | 2020-10-22 |
| BR112021006622A2 (pt) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020076789A3 (en) | Combinations of anti-staphylococcus aureus antibodies | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
| WO2020006374A3 (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EP4374922A3 (en) | Anti-c5 antibodies and uses thereof | |
| WO2020023644A3 (en) | Antibody directed against s. aureus clumping factor a (clfa) | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| PH12021550332A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| EA201991643A1 (ru) | Человеческие антитела к токсину гемолизину а s.aureus | |
| MX2021004114A (es) | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| PH12022551398A1 (en) | Anti-mertk antibodies and methods of use thereof | |
| JO3565B1 (ar) | الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها | |
| EA201990222A1 (ru) | Антитела к o2 и пути их применения | |
| EP3947447A4 (en) | ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY FOR THE TREATMENT OF TUMORS | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
| CL2023003331A1 (es) | Anticuerpos anti-tmprs66 y usos de los mismos. | |
| WO2019094533A8 (en) | Angptl8-binding agents and methods of use thereof | |
| WO2019246176A8 (en) | Anti-factor xii/xiia antibodies and uses thereof |